Table 1:

Baseline characteristics

	Patients n=217
Age, years	57 (48–64)
Sex
Male	120 (55%)
Female	97 (45%)
Region
Europe	94 (43%)
Asia	53 (24%)
North America	48 (22%)
Rest of world	22 (10%)
Race
White	112 (52%)
Asian	57 (26%)
Black or African American	6 (3%)
Other or not reported	42 (19%)
ECOG performance status*	n=215
0	65 (30%)
1	149 (69%)
2†	1 (<1%)
Time from progression/relapse on the last line of treatment to first dose, months‡	n=214 1.25 (0·82–2·14)
Metastatic sites
Presence of metastases sites	179 (83%)
Lymph node	119 (55%)
Liver	99 (46%)
Lung	94 (43%)
Bone	49 (23%)
Adrenal gland	17 (8%)
Brain	12 (6%)
Spinal cord	5 (2%)
Other	68 (31%)
Number of body sites with metastatic disease§
Median	2 (2–3)
1	40 (22%)
2	50 (28%)
≥3	89 (50%)
Prior systemic therapy in advanced/metastatic setting
Chemotherapy	215 (99%)
Immunotherapy	67 (31%)
Other systemic therapy	91 (42%)
Number of prior lines of anticancer therapies
Median	2 (2–4)
1	50 (23%)
2	67 (31%)
≥3	100 (46%)
Tumour types
Cholangiocarcinoma	31 (14%)
High-grade glioma	30 (14%)
Pancreatic cancer	18 (8%)
Breast cancer	16 (7%)
Squamous cell head and neck cancers	15 (7%)
Squamous NSCLC	14 (7%)
Non-squamous NSCLC	9 (4%)
Carcinoma of unknown primary	8 (4%)
Colorectal cancer	8 (4%)
Endometrial cancer	8 (4%)
Oesophageal cancer	8 (4%)
Gastric cancer	8 (4%)
Ovarian cancer	8 (4%)
Low-grade glioma	7 (3%)
Cervical cancer	6 (3%)
Salivary gland cancer	5 (2%)
Soft tissue sarcoma	3 (1%)
Prostate cancer	2 (1%)
Others	13 (6%)

Data are n (%) or median (IQR).

^*ECOG performance status is only applicable to adults.

^†One patient was enrolled with an ECOG performance status score of 2, which did not meet protocol eligibility criteria.

^‡Applicable only to patients with non-missing values for progression/relapse date of last line of treatment.

^§Metastatic site with other will be considered as one body site.

ECOG=Eastern Cooperative Oncology Group. NSCLC=non-small cell lung cancer.